Azur sues Barr over clozapine ODT
This article was originally published in Scrip
Azur Pharma and Cima Labs have filed suit in the US District Court for the District of Delaware againstBarr Laboratories, alleging patent infringement related to Barr's generic version of the schizophrenia product FazaClo (clozapine) orally disintegrating tablets, thus triggering the 30-month stay of approval. Azur had received notice that Barr filed an ANDA with a paragraph IV challenge to two of four Orange Book-listed patents – the '981 and the '392, expiring in April 2018, and licensed from Cima. An ex parte re-examination of the '981 patent was requested in 2005, and after filing a reply brief Cima recently requested oral argument before the Board of Patent Appeals and Interferences for the patent; an inter partes re-examination of the '392 patent was filed by KV Pharmaceutical in 2006 and is moving through the examiner's office. Barr believes it is the first to file an ANDA for the product, which generated about $34 million in US sales in the 12 months to end-June for the 25mg and 100mg doses.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.